ICCM

IceCure Medical (ICCM)

IceCure Medical Ltd

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:ICCM

1 2 3 4 5 6 7 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/12/16	22:30	PR Newswire (US)	Data on IceCure's ProSense® Cryoablation for Low-Risk Breast Cancer Presented at Radiological Society of North America's 2024 Annual Meeting	NASDAQ:ICCM	IceCure Medical Ltd
2024/12/05	22:35	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ICCM	IceCure Medical Ltd
2024/12/05	22:30	PR Newswire (US)	IceCure's ProSense® Cryoablation Safe and Effective in Destruction of Kidney Tumors with 88.7% Recurrence-Free Rate Based on Interim ICESECRET Study Results	NASDAQ:ICCM	IceCure Medical Ltd
2024/11/26	22:35	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ICCM	IceCure Medical Ltd
2024/11/26	22:30	PR Newswire (US)	IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense® Cryoablation	NASDAQ:ICCM	IceCure Medical Ltd
2024/11/25	22:50	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ICCM	IceCure Medical Ltd
2024/11/25	22:30	PR Newswire (US)	IceCure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance from Japan's Patent Office	NASDAQ:ICCM	IceCure Medical Ltd
2024/11/20	22:30	PR Newswire (US)	IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024	NASDAQ:ICCM	IceCure Medical Ltd
2024/11/19	22:30	PR Newswire (US)	IceCure's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health	NASDAQ:ICCM	IceCure Medical Ltd
2024/11/15	11:38	Edgar (US Regulatory)	Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:ICCM	IceCure Medical Ltd
2024/11/09	00:05	Edgar (US Regulatory)	Form F-1/A - Registration statement for certain foreign private issuers: [Amend]	NASDAQ:ICCM	IceCure Medical Ltd
2024/11/08	21:08	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ICCM	IceCure Medical Ltd
2024/11/08	21:00	PR Newswire (US)	FDA Advisory Panel Votes in Favor of IceCure's ProSense® Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast Cancer	NASDAQ:ICCM	IceCure Medical Ltd
2024/11/06	06:41	Edgar (US Regulatory)	Form F-1/A - Registration statement for certain foreign private issuers: [Amend]	NASDAQ:ICCM	IceCure Medical Ltd
2024/10/29	21:30	PR Newswire (US)	Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Authorization Receives Large Number of Public Comments from Stakeholders	NASDAQ:ICCM	IceCure Medical Ltd
2024/10/21	21:40	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ICCM	IceCure Medical Ltd
2024/10/21	21:30	PR Newswire (US)	IceCure Receives Notice of Allowance from U.S. Patent and Trademark Office for its Next-Generation Cryoablation System	NASDAQ:ICCM	IceCure Medical Ltd
2024/10/16	05:22	Edgar (US Regulatory)	Form F-1 - Registration statement for certain foreign private issuers	NASDAQ:ICCM	IceCure Medical Ltd
2024/10/07	21:30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ICCM	IceCure Medical Ltd
2024/10/07	21:15	PR Newswire (US)	IceCure's ProSense® Featured in 6 Global Studies on Cryoablation of Breast Tumors at the 2024 European Society of Breast Imaging Conference	NASDAQ:ICCM	IceCure Medical Ltd
2024/09/24	21:30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ICCM	IceCure Medical Ltd
2024/09/24	21:15	PR Newswire (US)	IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense® Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free Rate	NASDAQ:ICCM	IceCure Medical Ltd
2024/09/16	21:15	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ICCM	IceCure Medical Ltd
2024/09/16	21:00	PR Newswire (US)	Study Published in the British Journal of Radiology Demonstrates IceCure's ProSense® is a Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of the Lung, Bone, and Soft Tissues	NASDAQ:ICCM	IceCure Medical Ltd
2024/09/12	21:10	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ICCM	IceCure Medical Ltd
2024/09/12	21:00	PR Newswire (US)	IceCure Announces FDA Advisory Panel Meeting Date for Marketing Authorization of ProSense® in Early-Stage Low Risk Breast Cancer Scheduled for November 7, 2024	NASDAQ:ICCM	IceCure Medical Ltd
2024/09/04	21:30	PR Newswire (US)	IceCure to Meet Institutional Investors at the H.C. Wainwright and Lake Street Capital Markets Conferences	NASDAQ:ICCM	IceCure Medical Ltd
2024/08/28	21:45	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ICCM	IceCure Medical Ltd
2024/08/28	21:30	PR Newswire (US)	USPTO Grants Notice of Allowance for Additional Patent on IceCure's Novel Cryogenic Pump Technology: Reinforces IceCure's Global IP Leadership in Cryoablation Technologies	NASDAQ:ICCM	IceCure Medical Ltd
2024/08/20	22:03	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ICCM	IceCure Medical Ltd